Skip to content
Home page - Centenary Institute Centenary Institute

Primary menu

  • Research
        • Research

          The latest medical research into our most complex health challenges across cancer, cardiovascular disease and inflammation

          Learn more

        • Cancer
        • Inflammation
        • Cardiovascular
        • Programs
        • Laboratories
        • Diseases
        • Expertises
        • Services and instrumentation
  • Support us
        • Support us

          By supporting the Centenary Institute you can help improve human health through excellence in medical research

          Learn more

        • Workplace giving
        • Host or join a fundraiser
        • Gift in your Will
        • Donate in Memory
  • Impact
        • Impact

          Our research develops new diagnostics, treatments and cures for some of the most deadly and debilitating diseases affecting society today

          Learn more

        • Breakthroughs
        • Community and research
        • Real stories
  • Health hub
        • Health hub

          A range of practical information to assist in the possible preventions to disease through evidence-based research on how the body works.

          Learn more

        • Inflammation
        • The Good Gut Anti-Inflammatory Diet
        • Ageing
        • Exercise Snack Program
  • News & events
        • News & Events

          Explore the latest research breakthroughs and ways you can take part in our series of digital and in-person events

        • News
        • Events
        • Media Hub
  • About us
        • About us

          We are world-leading independent medical research institute that drives collaboration to accelerate and translate solutions to our most complex health challenges

          Learn more

        • Governance
        • Corporate information
        • Annual reports
        • Our researchers
        • Careers and studies
        • Contact
  • Donate
    Centenary Institute > News > New enzyme a target for cancer treatment

New enzyme a target for cancer treatment

Date time 14 July, 2015

Researchers at the Centenary Institute in Sydney have uncovered new information about an enzyme called DPP9 that they believe to be a potential therapeutic target for limiting tumour growth and its ability to spread to and in the liver.

Centenary’s researchers have shown that the DPP9 enzyme can regulate human liver cancer cell growth and movement. In addition, they have bred mice that lack DPP9 and shown that newborn mice need the enzyme to survive, highlighting its importance.

The results have shown that up to 100 molecules in the human body are probably de-­‐activated by DPP9 and many of these play important roles in either immunity or in regulating energy use and storage. The power of this enzyme is so great that it needs to be regulated. The aim of the next phase of the research is to discover how the cells of the body achieve this naturally.

Associate Professor Mark Gorrell, who discovered DPP9, is currently undertaking an extensive study of the enzyme and its functionalities. He and his team are aiming to discover what key molecules are deactivated by DPP9 and therefore how to exploit the enzyme’s functionalities for clinical use. The research could lead to major breakthroughs in the treatment of cancer, as well as in understanding the immune system and growth of stem cells.

The team is following the same strategic approach that led to the discovery of the functions of a similar enzyme, DPP4, the most successful new diabetes drug target this century and the safest. By focusing on the mechanisms of the enzyme from a basic biochemistry perspective, they are developing an understanding of how it acts inside both normal cells and cancer cells.

The work to date has recently been published in the highly prestigious FEBS Journal, the leading journal of the Federation of European Biochemists.

This paper itself is a close collaboration with Dr Andrew Stephens and his staff at Hudson Institute of Medical Research at Monash University as well as involving Dr Ruth Geiss-Friedlander of Georg-­August-­University in Germany. Associate Professor Gorrell’s team includes talented PhD Students Katerina Ajami, Denise Ming Tse Yu, JooHong Park, Tsun-­Wen Yao, Yiqian Chen, Hui Emma Zhang and Margaret Gall who have all played key roles in the results achieved.

For further information about the Centenary Institute’s Molecular Hepatology Laboratory click here.

Media enquires

For all media and interview enquiries, please contact Tony Crawshaw, Media and Communications Manager

Phone number Phone Number 0402 770 403

Email Email t.crawshaw@centenary.org.au

Recent Stories

  • New funding to advance gene therapies

    Researchers at the Centenary Institute and the Sydney Local Health District (SLHD) have been awarded $500,000 from CUREator, Australia’s national biotech incubator, to develop new technology to improve the safe and effective delivery of gene therapy.
    News Type: Media release
    Date 24 May 2023
  • ABC Health Report interviews Professor John Rasko AO

    Professor John Rasko AO, Head of the Gene and Stem Cell Therapy Program at the Centenary Institute has been interviewed by Dr Norman Swan on Radio National’s Health Report about gene therapy treatment for Duchenne muscular dystrophy as well as the status of gene therapy in the clinic generally.
    News Type: Media coverage
    Date 16 May 2023
  • Prestigious editorial board appointment for Associate Professor Andy Philp

    Associate Professor Andy Philp – Director of the Centenary Institute’s Centre for Healthy Ageing and an internationally renowned expert in skeletal muscle wasting disorders ¬ has been invited onto the editorial board of the respected Journal of Cachexia, Sarcopenia and Muscle (JCSM).
    News Type: Research News
    Date 08 May 2023
  • How can cardiovascular healthcare be ‘greener’?

    A new review has shown how medical professionals in cardiology can help reduce healthcare’s carbon footprint, by making small, low-cost changes in how they work. The review, published today in the prestigious Open Heart journal, explores the environmental impact of cardiovascular healthcare.
    News Type: Media release
    Date 03 May 2023

Subscribe to receive news on
research updates and free events

Newsletter

The Centenary Institute is a world-leading independent Medical Research Institute.

We acknowledge the Gadigal of the Eora Nation, the traditional custodians of the Country on which the Centenary Institute stands.

About

  • About
  • Governance
  • Corporate information

Research

  • Programs
  • Our researchers
  • News
  • Media hub

Careers & studies

  • Career opportunities
  • Life at Centenary

Links

  • Contact
  • Privacy statement

Contact us

Building 93, Royal Prince Alfred Hospital
Missenden Rd
Camperdown NSW 2050 Australia
Telephone +61 2 9565 6100
Fax +61 2 9565 6101

Contact Privacy

Centenary Institute ABN 22 654 201 090 (DGR 1) • Centenary Institute Medical Research Foundation ABN 85 778 244 012 (DGR 2)
© 2017 Centenary Institute of Cancer Medicine and Cell Biology.

  • Linkedin
  • Facebook
  • Twitter
  • Youtube
  • Instagram